Evidence map›Paper›PMID 37064811›Full record

ArticleSovremennye tekhnologii v meditsine2022

Messenger RNA of

A V Alyasova, Z V Amoev, O O Shkola, D V Novikov, S G Selivanova, V V Novikov

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

A V AlyasovaProfessor, Department of Oncology, Radiation Therapy and Radiation Diagnostics; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
Z V AmoevUrologist; Volga District Medical Centre of Federal Medical Biological Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603109, Russia.
O O ShkolaPhD Student, Department of Molecular Biology and Immunology; National Research Lobachevsky State University of Nizhni Novgorod, 23 Prospekt Gagarina, Nizhny Novgorod, 603950, Russia.
D V NovikovLeading Researcher; Blokhina Scientific Research Institute of Epidemiology and Microbiology of Nizhny Novgorod, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 71 Malaya Yamskaya St., Nizhny Novgorod, 603950, Russia.
S G SelivanovaSenior Researcher; Blokhina Scientific Research Institute of Epidemiology and Microbiology of Nizhny Novgorod, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 71 Malaya Yamskaya St., Nizhny Novgorod, 603950, Russia.
V V NovikovProfessor, Department of Molecular Biology and Immunology; National Research Lobachevsky State University of Nizhni Novgorod, 23 Prospekt Gagarina, Nizhny Novgorod, 603950, Russia; Leading Researcher; Blokhina Scientific Research Institute of Epidemiology and Microbiology of Nizhny Novgorod, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 71 Malaya Yamskaya St., Nizhny Novgorod, 603950, Russia Head of the Laboratory of Immunochemistry; Blokhina Scientific Research Institute of Epidemiology and Microbiology of Nizhny Novgorod, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 71 Malaya Yamskaya St., Nizhny Novgorod, 603950, Russia.
Advanced Radiation Therapy (United States) · USFederal Medical-Biological Agency · RUFederal Service for Surveillance on Consumer Rights Protection and Human Wellbeing · RUN. I. Lobachevsky State University of Nizhny Novgorod · RUNizhniy Novgorod Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina · RUPrivolzhsky Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Materials and Methods: We used 125 tumor samples from patients with a histologically confirmed diagnosis of renal cancer T Results: mRNA of the Conclusion: In tumor tissue samples from patients with clear cell renal cancer, the predominant production of the

Indexed as

Carcinoma, Renal CellGenetic Predisposition to DiseaseGPI-Linked ProteinsHumansPilot ProjectsReceptors, IgGFCGR3A protein, humanFCGR3B protein, humanGPI-Linked ProteinsReceptors, IgGmonitoring renal cancer markersmRNA of FCGR3A genemRNA of FCGR3B gene

Identifiers

PMID37064811
PMCPMC10090913
OpenAlexW4283736796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.